Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - COLLEGIUM PHARMACEUTICAL, INC | coll-20201231xex32d1.htm |
| EX-32.2 - EX-32.2 - COLLEGIUM PHARMACEUTICAL, INC | coll-20201231xex32d2.htm |
| EX-31.2 - EX-31.2 - COLLEGIUM PHARMACEUTICAL, INC | coll-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - COLLEGIUM PHARMACEUTICAL, INC | coll-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - COLLEGIUM PHARMACEUTICAL, INC | coll-20201231xex21d1.htm |
| EX-4.5 - EX-4.5 - COLLEGIUM PHARMACEUTICAL, INC | coll-20201231xex4d5.htm |
| 10-K - 10-K - COLLEGIUM PHARMACEUTICAL, INC | coll-20201231x10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-234329 and 333-237200 on Form S-3 and Registration Statement Nos. 333-207744, 333-218767, 333-225498, 333-233092, and 333-245649 on Form S-8 of our reports dated February 25, 2021, relating to the consolidated financial statements of Collegium Pharmaceutical, Inc. and subsidiaries (the “Company”), and the effectiveness of the Company's internal control over financial reporting, appearing in this Annual Report on Form 10-K of Collegium Pharmaceutical, Inc. for the year ended December 31, 2020.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 25, 2021